Stemedica

STEMEDICA AWARDED U.S. PATENT FOR TRANSGENIC THERAPEUTIC STEM CELLS

Stemedica Cell Technologies Inc. received United States Patent No. 9080184 entitled “Transgenic Therapeutic Stem Cells and Methods for Their Use and Manufacture.” The patent issued on July 14, 2015.

FDA GRANTS IND APPROVAL FOR PHASE IIA CLINICAL TRIAL USING STEMEDICA’S ITMSC THERAPY TO TREAT ALZHEIMER’S DISEASE

Stemedica Cell Technologies, Inc. received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer’s disease (AD), the sixth leading cause of death in the United States.

More news >>

Transforming Medicine for the 21st Century

Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.

Watch a short informative video about our company and the unique technological advantages of our proprietary adult stem cells.

Stemdica Overview Video

StemCutis

Unique stem cell-based products to treat dermatological diseases and improve the appearance of patients’ skin

The company is currently in clinical trials with therapies for photoaged skin. StemCutis is using stem cells and their factors to treat a range of conditions that affect skin and tissue appearance: compromised skin, diabetic ulcers, hair loss, burns and hypertrophic, hypotrophic and keloid scars.

Further information >>

Cardio Cell

Applying stem-cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication.

Further information >>